STOCK TITAN

Vaccinex, Inc. - $VCNX STOCK NEWS

Welcome to our dedicated page for Vaccinex news (Ticker: $VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.

The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.

Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.

Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.

Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
conferences

FAQ

What is Vaccinex, Inc.?

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies, vaccines, and biologic products to treat serious diseases, including cancer and autoimmune diseases.

Where is Vaccinex, Inc. located?

Vaccinex, Inc. is based in Rochester, NY.

What is Vaccinex's lead drug candidate?

Vaccinex's lead drug candidate is pepinemab, which targets semaphorin 4D (SEMA4D) and is being studied for its potential to treat cancer and neurodegenerative diseases.

What is the focus of Vaccinex's research?

Vaccinex focuses on treating serious diseases with unmet medical needs, such as cancer, multiple sclerosis, and other autoimmune diseases.

What clinical studies is pepinemab involved in?

Pepinemab is currently being evaluated in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease.

What is the ActivMAb platform?

ActivMAb is Vaccinex's proprietary drug discovery platform that aids in the development of its innovative therapeutic products.

Who are Vaccinex's research partners?

Vaccinex collaborates with world-class academic institutions and biotechnology companies for its discovery research.

What recent milestone has Vaccinex achieved?

Vaccinex recently completed a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards.

How is Vaccinex funded?

Vaccinex has received significant investments and grants, including funding from the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.

Who leads the development team at Vaccinex?

Vaccinex's development team is led by experienced industry veterans with expertise in various fields such as therapeutic biologics research, manufacturing, and regulatory affairs.

Vaccinex, Inc.

Nasdaq:VCNX

VCNX Rankings

VCNX Stock Data

10.86M
591.10k
6.76%
41.7%
0.44%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
ROCHESTER